Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

Cancer Science

Junshik Hong³  Hyun Seon Woo³  Hyunchul Kim²  Hee Kyung Ahn³  Sun Jin Sym³  Jinny Park³  Jeong Yeal Ahn¹  Eun Kyung Cho³  Dong Bok Shin³ 

[1]Department of Laboratory Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea

[2]Department of Pathology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea

[3]Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea

关键词: Anemia;    biomarkers;    diffuse large B‐cell lymphoma;    non‐Hodgkin's lymphoma;    prognosis;   

DOI  :  10.1111/cas.12544

来源: Wiley

【 摘 要 】

Abstract

The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with newly diagnosed diffuse large B-cell lymphoma treated with ≥1 cycle of R-CHOP were included. Hemoglobin level without red cell transfusion within 7 days of initiation of treatment was chosen as a parameter of baseline cancer-induced anemia. To investigate the clinical significance of chemotherapy-induced anemia and its recovery after completion of treatment, 87 patients in complete remission for ≥6 months from the time of the last cycle of R-CHOP were grouped and analyzed separately. Patients with a cancer-induced anemia of hemoglobin <10 g/dL showed inferior event-free and disease-free survival compared to those with hemoglobin ≥10 g/dL. This finding was observed irrespective of the status of pre-treatment bone marrow involvement. In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor. Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

【 授权许可】

CC BY-NC-ND   
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.